All In Biotech

Drug Trial Radar · NCT05815758

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)

Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 512 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

512

Actual

Start

Apr 20, 2023

Primary completion

Sep 18, 2023

Study completion Sep 18, 2023

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.

Conditions

  • Allergic Conjunctivitis

Interventions

  • Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)Drug

    Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)

  • Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solutionDrug

    Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to Day 42

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • 104- Arizona Eye Center

    Chandler, Arizona

  • 103- Seidenberg Protzko Eye Associates

    Havre de Grace, Maryland

  • 101 - Andover Eye Associates

    Andover, Massachusetts

  • 105- NC Eye Associates

    Apex, North Carolina

  • 107 Total Eye Care, PA

    Memphis, Tennessee

  • 106- Emerson Research Institute, Inc.

    Falls Church, Virginia

  • 102 - Piedement Eye Center

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.